Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Secondary Prevention of Venous Thrombo Embolism (VTE).

ClinicalTrials.gov ID: NCT00329238

Public ClinicalTrials.gov record NCT00329238. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.

Study identification

NCT ID
NCT00329238
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
2,867 participants

Conditions and interventions

Interventions

  • Dabigatran Drug
  • Warfarin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2006
Primary completion
Sep 30, 2010
Completion
Not listed
Last update posted
May 18, 2014

Started 2006

United States locations

U.S. sites
18
U.S. states
16
U.S. cities
18
Facility City State ZIP Site status
1160.47.01035 Boehringer Ingelheim Investigational Site Mobile Alabama
1160.47.01056 Boehringer Ingelheim Investigational Site Hartford Connecticut
1160.47.01044 Boehringer Ingelheim Investigational Site Clearwater Florida
1160.47.01019 Boehringer Ingelheim Investigational Site Augusta Georgia
1160.47.01008 Boehringer Ingelheim Investigational Site Decatur Georgia
1160.47.01014 Boehringer Ingelheim Investigational Site Baltimore Maryland
1160.47.01018 Boehringer Ingelheim Investigational Site Roxbury Crossing Massachusetts
1160.47.01023 Boehringer Ingelheim Investigational Site Detroit Michigan
1160.47.01009 Boehringer Ingelheim Investigational Site Saint Louis Park Minnesota
1160.47.01031 Boehringer Ingelheim Investigational Site Lebanon New Hampshire
1160.47.01036 Boehringer Ingelheim Investigational Site Albuquerque New Mexico
1160.47.01027 Boehringer Ingelheim Investigational Site Chapel Hill North Carolina
1160.47.01039 Boehringer Ingelheim Investigational Site Winston-Salem North Carolina
1160.47.01030 Boehringer Ingelheim Investigational Site Grand Forks North Dakota
1160.47.01013 Boehringer Ingelheim Investigational Site Toledo Ohio
1160.47.01052 Boehringer Ingelheim Investigational Site Altoona Pennsylvania
1160.47.01055 Boehringer Ingelheim Investigational Site Summerville South Carolina
1160.47.01017 Boehringer Ingelheim Investigational Site Richmond Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 257 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00329238, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 18, 2014 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00329238 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →